New tools to tackle inflammatory arthritis

Novel therapies to reduce the progressive and destructive nature of inflammatory joint disease are always welcome, provided that safety is not compromised. Among the many 2015 studies in the field, we highlight a targetable mechanism of uric-acid-induced inflammation in gouty arthritis and the expected efficacy-but unforeseen safety concerns-of anti-IL-17 antibodies.